⚕ GalenOps field
←

SITE010-0238

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-12-02

AEs
6
Serious
0
Dropout signal
–

Adverse events

severe assessed

Grade 3 Aspartate aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-02-27 (study day 72); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 97); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-28 (study day 101); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-04-13 (study day 117); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-04-15 (study day 119); relationship: N

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-06-01 (study day 166); relationship: not assessed

Data queries

No data queries.